Immatics Announces Collaboration With Moderna

Reston – September 11, 2023 – Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna. Lawyers Kenneth Krisko and Stephanie Palmer led the Cooley team advising Immatics.

The collaboration combines Immatics’ T cell receptor (TCR) platform with Moderna’s cutting-edge mRNA technology. Immatics will receive an upfront payment of $120 million, and the company is eligible to receive development, regulatory and commercial milestone payments that could exceed $1.7 billion.

Cooley previously advised Immatics on its collaborations with Bristol Myers Squibb in June 2022 and December 2021, and its collaboration with Roche in December 2013.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.